CDT Equity Shares Scheduled to Reverse Split on Tuesday, September 29th (NASDAQ:CDT)

CDT Equity Inc. (NASDAQ:CDT)’s stock is scheduled to reverse split on the morning of Tuesday, September 29th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 28th.

CDT Equity Trading Down 33.9%

CDT traded down $0.04 on Friday, hitting $0.08. 25,908,804 shares of the company’s stock were exchanged, compared to its average volume of 1,132,005. The firm has a market cap of $63,200.00, a PE ratio of -0.00 and a beta of 1.48. CDT Equity has a twelve month low of $0.08 and a twelve month high of $1,778.00. The stock has a fifty day moving average of $1.93 and a two-hundred day moving average of $24.26.

CDT Equity (NASDAQ:CDT) last issued its earnings results on Wednesday, August 12th. The company reported ($8.71) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen upgraded CDT Equity from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, CDT Equity has a consensus rating of “Sell”.

About CDT Equity

CDT Equity, Inc, traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases.

The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress.

Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines.